logo
NASA confirms two major solar flares on sun, which can cause blackouts on Earth

NASA confirms two major solar flares on sun, which can cause blackouts on Earth

CTV News21-05-2025

NASA's Solar Dynamics Observatory captured this image of a solar flare — seen as the bright flash on the left – on May 14. The image shows a subset of extreme ultraviolet light that highlights the extremely hot material in flares and which is colorized in red. (NASA/SDO)
NASA confirmed two solar flares erupting on the surface of the sun last week, an event that they say can impact radio communications, electric power grids, navigation signals and pose risks to spacecrafts and astronauts in the orbit.
The first flare occurred May 13 at 11:38 a.m. EDT, and was recorded by NASA's Solar Dynamics Observatory. Classified as an X1.2 flare, NASA says the 'X-class denotes the most intense flares.'
The second solar flare, peaking at 4:25 a.m. EDT on May 14, was also recorded by the Solar Dynamics Observatory. This flare was classified as an X2.7 flare.
The flares occurred on sunspot AR4087, an extremely active region on the sun.
Space photographer Vincent Ledvina, who studies space physics at the University of Alaska-Fairbanks, reacted with a 'wow' when studying the flare ups.
'This is getting intense, especially as this active region turns closer into view,' Ledvina said on social media.
What are 'solar storms'?
A solar storm is a sudden explosion of particles, energy, magnetic fields and material blasted into the solar system by the sun, NASA explains.
A solar storm is caused due to a 'tangled mess of magnetic fields' created by the sun. According to NASA, these magnetic fields get twisted up as the sun rotates – with its equator rotating faster than its poles.
'Solar storms typically begin when these twisted magnetic fields on the sun get contorted and stretched so much that they snap and reconnect (in a process called magnetic reconnection), releasing large amounts of energy,' the space agency said.
A solar storm can create major disturbances in the Earth's magnetic field, called a geomagnetic storm, the space agency's website reads. This storm can cause radio blackouts, power outages and beautiful auroras brought on by coronal mass ejections (CME), which occurs when charged solar particles pass through the Earth's atmosphere.
What are 'solar flares'?
A solar flare is an intense burst of radiation or light on the sun, according to the space agency.
'These flashes span the electromagnetic spectrum – including X-rays, gamma rays, radio waves and ultraviolet and visible light,' NASA said.
Solar flares are the most powerful explosions in the solar system — the biggest ones can have as much energy as 'a billion hydrogen bombs,' according to NASA.
Solar flares are classified as A, B, C, M and X – with X being the strongest flare and A being the weakest.
'The energy from a flare travels at the speed of light, which means it reaches Earth about eight minutes after a flare happens,' NASA said. 'Essentially, by the time we see a flare, most of its effects are here.'
Solar flare
Material rises from the edge of the sun, as seen in extreme ultraviolet light by NASA's Solar Dynamics Observatory. (NASA/SDO)
However, the harmful radiation from a flare does not affect us on the ground since we are shielded by Earth's atmosphere and magnetic field. But a strong flare can disrupt communications that pass through the upper atmosphere and affect satellites and other spacecrafts.
'There are five sunspot regions on the Earth-facing disc, however these are mostly small, simple and with little sign of growth,' the Met Office said in its latest space weather forecast. 'The most notable is in the north-centre, however this is overall much simpler and less active than a few days ago.'
Another strong solar flare was recorded previously by NASA's Solar Dynamics Observatory, peaking at 11:38 a.m. EDT on May 13. This flare is classified as an X1.2 flare, NASA says.
The most powerful flare ever measured was recorded in 2003 as an X28, before NASA's sensors were overwhelmed by it.
CTV News previously wrote that NASA had warned of potential blackouts on Earth due to these specific solar flares. However, NASA has said that solar flares can cause blackouts on Earth.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report

Globe and Mail

time7 hours ago

  • Globe and Mail

Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report

ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest data from a Phase Ib/II study of the investigational Bcl-2 inhibitor, lisaftoclax (APG-2575), in combination with hypomethylating agent azacitidine in patients with treatment-naïve (TN) or prior venetoclax-exposed myeloid malignancies, in an oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community. As Ascentage Pharma returns to the ASCO Annual Meeting for the eighth consecutive year, two studies of lisaftoclax and MDM2-p53 inhibitor alrizomadlin (APG-115), key drug candidates in the company's apoptosis-targeted pipeline, have been selected for presentations, including an oral presentation. This oral presentation reported results from a multi-country, multi-center Phase Ib/II study of lisaftoclax, which as of data cutoff in April 2025, enrolled a total of 103 patients, including patients with TN or relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Findings of this study once again underscored the promising antitumor activity and manageable tolerability of lisaftoclax in myeloid malignancies. Furthermore, for the first time, this study reported responses in venetoclax-refractory patients who received lisaftoclax, thus suggesting that lisaftoclax has favorable antitumor activity and is differentiated from other drugs in the same class. Lisaftoclax is a novel Bcl-2 inhibitor developed by Ascentage Pharma. In November 2024, the New Drug Application (NDA) for lisaftoclax for the treatment of R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was accepted and granted a Priority Review designation by the Center for Drug Evaluation (CDE) of China's National Medical Product Administration (NMPA). With this submission, lisaftoclax has become the first China-developed Bcl-2 inhibitor to reach NDA submission in China, and the second Bcl-2 inhibitor with submitted NDAs anywhere in the world. At present, lisaftoclax is being evaluated in four global registrational Phase III studies in major indications such as CLL/SLL, AML, and MDS, including a US Food and Drug Administration (FDA)-cleared multi-country, registrational Phase III trial. Patricia Kropf, MD, Principal Investigator of the study from Novant Health Cancer Institute, commented, 'In this global, multicenter study, lisaftoclax in combination with azacitidine showed promising efficacy and a tolerable safety profile for patients with treatment-naïve or R/R AML and MDS. This data supports the upcoming Phase III study using the combination therapy for this patient population. Interestingly, lisaftoclax showed the potential to overcome resistance to venetoclax in patients who failed prior treatment with venetoclax, suggesting that it might bring improved treatment outcome. We look forward to releasing more data from this study which will further validate lisaftoclax's broad therapeutic potential.' Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'In previous studies, lisaftoclax combined with azacitidine has already demonstrated significant activity in patients with various myeloid malignancies. In this oral presentation, we report the latest data from a multi-country, multicenter Phase Ib/II study that showed promising antitumor activity and good tolerability of the combination regimen in myeloid malignancies such as AML and MDS. In particular, lisaftoclax has shown therapeutic potential in venetoclax-refractory patients, making this study the first that reported a Bcl-2 inhibitor overcoming drug resistance to another Bcl-2 inhibitor, thus suggesting that lisaftoclax may bring about a breakthrough to the treatment of myeloid malignancies. For now, lisaftoclax is being evaluated in multi-countries, registrational Phase III studies in AML and MDS. We remain committed to our mission of addressing unmet clinical needs in China and around the world and plan to further accelerate our clinical programs to bring more novel therapeutics to patients as soon as possible.' Highlights of this abstract selected for presentation at ASCO 2025 are as follows: Phase 1b/2 Study of Lisaftoclax (APG-2575) Combined with Azacitidine (AZA) in Patients with Treatment-Naïve or Prior Venetoclax-Exposed Myeloid Malignancies Abstract #: 6505 Format: Oral Presentation Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Principal Authors: Michael Francis Leahy, MBChB, Royal Perth Hospital, Australia; Shaun Fleming, MBBS(Hons), PhD, The Alfred Hospital & Australian Centre for Blood Diseases, Australia; Patricia Kropf, MD, Novant Health Cancer Institute, United States, et al. Highlights: Background: AML and MDS are hematologic malignancies with poor prognoses. Hypomethylating agents (HMAs) AZA and decitabine are approved for MDS and AML and have been shown to prolong survival in patients. However, additional treatment options that improve clinical outcomes, such as complete response (CR) and overall survival (OS), are needed. Lisaftoclax is an investigational, orally active, small-molecule Bcl-2 inhibitor that has shown enhanced treatment responses in AML and MDS when combined with AZA in preclinical 1 and clinical 2 studies. Efficacy results: As of the data cutoff in April 2025, 22 of 28 venetoclax-refractory patients with R/R AML/ Mixed Phenotype Acute Leukemia (MPAL) were efficacy-evaluable, among whom, the overall response rate (ORR) was 31.8%, including 22.8%, 4.6%, and 4.6% achieving CR/CR with incomplete hematologicrecovery (CRi), partial response (PR), and the morphologic leukemia-free state (MLFS), respectively. All responsive patients had received multiple lines of therapy that included venetoclax, and most of them (71%, 5/7) harbored the TP53 mutation and had a complex chromosomal karyotype at baseline. In 6 efficacy-evaluable patients with newly diagnosed (ND) AML/MPAL, the ORR was 83.3%, with CR/CRi and PR achieved by 33.3% and 50% of patients, respectively. In 44 efficacy-evaluable patients with R/R AML/MPAL, the ORR was 43.2%, with CR/CRi, PR, and MLFS achieved by 31.8%, 4.5%, and 6.8% of patients, respectively. In 15 efficacy-evaluable patients with ND MDS/chronic myelomonocytic leukemia (CMML), the ORR was 80%, with CR and marrow CR (mCR) achieved by 40% and 40% of patients, respectively. In 22 efficacy-evaluable patients with R/R MDS/CMML, the ORR was 50%, with CR, mCR, and PR achieved by 27.3%, 18.2%, and 4.5% of patients, respectively. Safety results: Lisaftoclax in combination with AZA was well tolerated, with a manageable profile. Common adverse events were mostly hematologic. Nonhematologic toxicity was uncommon. The majority of adverse events were manageable, reversible and tolerable. Conclusions: Lisaftoclax combined with AZA showed promising antitumor activity and favorable tolerability in patients with TN or R/R myeloid malignancies. Furthermore, lisaftoclax demonstrated the ability to overcome drug resistance to venetoclax, making this the first clinical study to report a Bcl-2 inhibitor overcoming venetoclax resistance. * Lisaftoclax (APG-2575) is an investigational compound and has not been approved by the US FDA. Reference: 1 Zhai Y, Tang Q, Fang DD, et al. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies. Clin Cancer Res. 2023;29:183-196. 2 Wang H, Wei X, Jiang Q, et al. Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms. Blood 2023;142(Suppl 1):2925. About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first third generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for newly diagnosed Ph + ALL patients and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematological malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with sub-optimal response, as well as global registrational Phase III trials for newly diagnosed CLL/SLL, AML and MDS patients. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma +86 512 85557777 Stephanie Carrington ICR Healthcare +1 (646) 277-1282 Media Relations: Sean Leous ICR Healthcare +1 (646) 866-4012

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe and Mail

time9 hours ago

  • Globe and Mail

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on June 2, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 137,400 shares of the Company's common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual's entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.28 per share, which is equal to the closing price of Zentalis' common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to the employees' continued service to Zentalis on each vesting date. About Zentalis Pharmaceuticals Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.

Following a weekend northern lights display, there's still a chance to see them tonight
Following a weekend northern lights display, there's still a chance to see them tonight

CBC

time11 hours ago

  • CBC

Following a weekend northern lights display, there's still a chance to see them tonight

Social Sharing There was a powerful geomagnetic storm over the weekend, resulting in beautiful displays of the northern lights from Canada down to the U.S. And there's a possibility that the colourful curtains in the sky could be visible once again on Monday night. The northern lights, or aurora borealis, occur when particles from the sun are carried along by fast-moving solar wind. Often this occurs due to a coronal mass ejection, or CME. This is a large expulsion of particles from the sun that travel faster than normal on the solar wind. One of these CMEs hit Earth on Saturday, resulting in auroras seen all over the world. The show continued into Sunday during daylight hours in Canada but then waned. But we are still feeling the effects of the CME interacting with our magnetic field, which means we may still get a show. The strength of a geomagnetic storm is measured using the Kp Index, ranging from one to nine. The higher the number, the stronger the storm. On Sunday, the Kp Index went as high as eight, but it fell to five by early Monday. Although it has dropped, that doesn't mean the show is over. But it's likely that it won't be as powerful or intense as this weekend's display. As Chris Ratzlaff, a seasoned aurora chaser from Airdrie, Alta., and the co-founder of the ever popular Alberta Aurora Chasers, said, there's "lots of potential [and] lots of uncertainty." "The probability is not high because there is uncertainty about the composition of the tail end of the CME," he said. "If conditions in the tail end of the CME remain favourable, then our odds for aurora will improve." Forecasting the northern lights is notoriously difficult. There are numerous conditions that need to be met, including how fast the wind is moving and whether the auroral oval — along which these particles interact with molecules that produce the colours of the lights — tips south, in our favour. The further south the hole dips, the further south the aurora are seen. And, as of Monday afternoon, the auroral oval was tipping south, in our favour. To see them, you should look north. For those further south in Canada, such as in southwestern Ontario, it's best to have a clear line of sight to the northern horizon. The other thing that many Canadians may have to deal with that could hamper any chances of seeing the northern lights is the smoke that is covering many parts of the country as forest fires spread in Western Canada. If the northern lights do show up tonight, don't expect an incredible display like the one from last May or last October. If it happens, this will likely be weaker.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store